Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.55 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.55 |
| ▸ | CHRNG | P07510 | 4/20 | 0.55 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.55 |
| ▸ | CHRND | Q07001 | 4/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30450072 | 0.98 | SLC6A2 (0.56) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL4399935 | 0.84 | CYP2B6 (0.59) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL836614 | 0.77 | TRPA1 (0.44) | ALDH1A1SMN1; SMN2HTTPOLBCES2 | |
| SCHEMBL836615 | 0.77 | TRPA1 (0.44) | ALDH1A1SMN1; SMN2HTTPOLBCES2 | |
| SCHEMBL2632778 | 0.76 | CES2 (0.58) | CYP2C19ALDH1A1POLBCES2CES1 | |
| SCHEMBL769768 | 0.75 | SLC6A3 (0.66) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL18074005 | 0.75 | POLB (0.48) | CYP2C19ALDH1A1SMN1; SMN2POLBCES2 | |
| SCHEMBL4401492 | 0.74 | NPC1 (0.48) | CYP2C19ALDH1A1SMN1; SMN2POLBCES2 | |
| Hydrochloric Acid SCHEMBL10618419 | 0.74 | SLC6A2 (0.67) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL30529376 | 0.73 | CES2 (0.54) | CYP2C19ALDH1A1POLBCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741383-A1 | COMPOUND AND USE THEREOF AS ANTI-CANCER DRUG | Tyligand Bioscience (Shanghai) Limited (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250312469-A1 | FL118 COMPLEXES FOR TARGETING DDX5, UbE2T or USP2a | CANGET BIOTEKPHARMA, LLC | 2025-10-09 | — | — | US | disclosed |
| US-12298320-B2 | Compound distribution in microfluidic devices | EMULATE, Inc. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250108064-A1 | PHOSPHATE PRODRUGS OF CANNABINOIDS | EMORY UNIVERSITY (US) | 2025-04-03 | — | — | US | disclosed |
| US-20250017932-A1 | Methods of Administering Elagolix | ABBVIE INC (US) | 2025-01-16 | — | — | US | disclosed |
| EP-3998073-B1 | DEVICES AND METHODS FOR SIMULATING A FUNCTION OF A LIVER TISSUE | EMULATE INC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240279612-A1 | LIVER ORGANOID MANUFACTURING METHODS, LIVER ORGANOIDS OBTAINED WITH THE SAME, AND USES THEREOF | HCS PHARMA (FR) | 2024-08-22 | — | — | US | disclosed |
| CN-118510544-A | Cannabinoids phosphate prodrugs | 爱莫里大学 | 2024-08-16 | — | — | CN | disclosed |
| US-12019083-B2 | Compound distribution in microfluidic devices | EMULATE, Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-4376893-A2 | PHOSPHATE PRODRUGS OF CANNABINOIDS | Emory University (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20220334139-A1 | COMPOUND DISTRIBUTION IN MICROFLUIDIC DEVICES | EMULATE, Inc. | 2022-10-20 | — | — | US | disclosed |
| US-20220257597-A1 | Methods of Administering Elagolix | ABBVIE INC. (US) | 2022-08-18 | — | — | US | disclosed |
| WO-2022165097-A1 | METHODS OF ADMINISTRATING ELAGOLIX | ABBVIE INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220168307-A1 | TREATMENT OF SMA | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220155328-A1 | COMPOUND DISTRIBUTION IN MICROFLUIDIC DEVICES | EMULATE, Inc. | 2022-05-19 | — | — | US | disclosed |
| EP-3998073-A1 | DEVICES AND METHODS FOR SIMULATING A FUNCTION OF A LIVER | Emulate, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3990186-A1 | COMPOUND DISTRIBUTION IN MICROFLUIDIC DEVICES | Emulate, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-1420795-A4 | AS-NEEDED ADMINISTRATION OF AN ANDROGENIC AGENT TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS INC (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1420795-A1 | AS-NEEDED ADMINISTRATION OF AN ANDROGENIC AGENT TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS | Vivus, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003011301-A1 | AS-NEEDED ADMINISTRATION OF AN ANDROGENIC AGENT TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220257597-A1 | Methods of Administering Elagolix | CYP2D6, CYP19A1, CYP2B6 | SLC6A2 1456/4885SLC6A3 1336/4885CHRNA1 1537/4885 |
| US-20250312469-A1 | FL118 COMPLEXES FOR TARGETING DDX5, UbE2T or USP2a | USP8, DDX18, UBE2T | SLC6A2 4485/4885SLC6A3 4109/4885CHRNA1 4732/4885 |
| US-20250017932-A1 | Methods of Administering Elagolix | CYP2D6, CYP19A1, CYP2B6 | SLC6A2 1456/4885SLC6A3 1336/4885CHRNA1 1537/4885 |
| US-20250108064-A1 | PHOSPHATE PRODRUGS OF CANNABINOIDS | CNR1, CNR2, PLCB3 | SLC6A2 653/4885SLC6A3 458/4885CHRNA1 1079/4885 |
| US-20220168307-A1 | TREATMENT OF SMA | SMN1; SMN2, MTPN, CPT1B | SLC6A2 3019/4885SLC6A3 4351/4885CHRNA1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.